Saxenda for kids in Mexico: what the evidence actually shows

What did @dravaleriamartin actually say?

Honestly? It's hard to tell. The transcript we're working from is a machine-generated mess, almost certainly an auto-caption failure on a Spanish-language video. What comes through clearly is that this bariatric doctor was discussing Saxenda (liraglutide), pediatric nutrition, and some kind of Mexican regulatory or protocol context, likely referencing COFEPRIS approval or dosing guidelines for children and adolescents. The phrase 'protocol of Saxena' and 'Dose años' (possibly 'doce años,' meaning twelve years) suggest she was explaining age-based eligibility or a clinical protocol for liraglutide use in minors.

The hashtags fill in gaps the transcript can't: #saxenda, #nutricionpediatrica, #niñosyadolescentes, and #cofepris paint a picture of a physician explaining liraglutide's regulatory status for pediatric weight management in Mexico. That's a legitimate and genuinely underreported topic. We just can't quote her directly with any confidence because the transcript is unreliable.

Does the science back this up?

If she's arguing liraglutide has a role in adolescent obesity treatment, the evidence mostly supports that position, with important caveats about long-term data and who actually qualifies.

The landmark trial here is the SCALE Teens study (Kelly et al., 2020, New England Journal of Medicine), a randomized controlled trial of 251 adolescents aged 12-17 with obesity. Participants on liraglutide 3.0 mg saw a mean BMI reduction of 4.64% versus a 1.62% increase in the placebo group. That's a statistically significant and clinically meaningful difference. The FDA approved Saxenda for adolescents aged 12 and older in 2020, making it the first GLP-1 receptor agonist cleared for pediatric obesity in the U.S.

COFEPRIS, Mexico's regulatory body, operates independently of the FDA, so its own approval timeline and criteria may differ. A physician explaining that regulatory distinction to Mexican parents is genuinely useful public health communication, assuming the content is accurate.

What did they get wrong (or right)?

We can't fact-check specifics we can't read. That's the real problem here. The transcript is so corrupted by auto-caption errors that assigning accuracy ratings to specific claims feels like guesswork dressed up as journalism. What we can say is this: the framing, a bariatric physician discussing pediatric liraglutide protocols in a regulatory context for a Mexican audience, is medically grounded. The SCALE Teens data is real. COFEPRIS oversight of GLP-1 medications for minors is a real and evolving issue.

What would concern us in any video like this: oversimplifying eligibility criteria (liraglutide isn't for every overweight child, it's indicated for obesity with a BMI at or above the 95th percentile), glossing over side effects like nausea, vomiting, and the rare but serious risk of pancreatitis, or implying this is a standalone treatment rather than an adjunct to lifestyle intervention. Whether she made those errors, we genuinely cannot confirm from this transcript.

What should you actually know?

Liraglutide for adolescents is legitimate medicine when used correctly, but the bar for 'correctly' is high and the context matters enormously. Here's what the evidence actually says.

First, eligibility is specific. The FDA indication covers adolescents 12 and older with a BMI at or above the 95th percentile and at least one weight-related comorbidity, or a BMI 30 kg/m2 or higher. This is not a drug for mildly overweight teens. Second, side effects in the SCALE Teens trial were consistent with the adult profile: nausea affected about 46% of the liraglutide group versus 17% placebo. That's not trivial for a child or family to manage. Third, the long-term data in pediatric populations is still limited. We know it works over 56 weeks. We don't have decade-long safety data in adolescents, and that uncertainty should be part of any honest conversation a physician has with families. Fourth, compounded liraglutide products are not equivalent to brand-name Saxenda. If a Mexican family is seeking this medication and encounters a compounded version, that is a different product with different quality controls, and a physician should say so plainly.

• Liraglutide 3.0 mg is FDA-approved for adolescents 12 and older with obesity (Kelly et al., 2020, NEJM)
• BMI must meet specific thresholds. This is not a general weight-loss tool for teens
• COFEPRIS approval status in Mexico may differ from FDA timelines and criteria
• Nausea affects roughly half of adolescent patients in clinical trials
• Long-term pediatric safety data beyond one year remains limited